Anti-inflammatory effects of ethanolic extract from Lagerstroemia indica on airway inflammation in mice.
OBJECTIVE
In the present study, we investigated whether the Lagerstroemia indica Linn (LI) extract has an anti-inflammatory effect on lung inflammation in ovalbumin-induced asthmatic mice.


METHODS
The LI extract was obtained from dried and powdered whole plants of LI using 80% ethanol. ELISA was performed to evaluate cytokine concentration. BALB/c mice were used as a mouse model of asthma after asthmatic induction by ovalbumin sensitization and inhalation. We examined the effects of the LI extract on leukocyte infiltration and mucus secretion using cell count and histological stain.


RESULTS
The amount of cytokines, such as interleukin (IL)-2, IL-4, IL-5, IL-13, and TNF-α, was increased in Jurkat cells using the extract from house dust mites. Increased cytokine concentrations were inhibited by the LI extract. The LI extract suppressed the increased expression of IL-6 after treatment with mite extract of EoL-1 cells and THP-1 cells. In an in vivo experiment using asthmatic mice, the LI extract significantly inhibited leukocytosis and eosinophilia in bronchoalveolar lavage (BAL) fluid and lung tissue samples. The LI extract inhibited the increase in mucus secretion by goblet cells, blocked the production of reactive oxygen species in BAL fluid cells, and blocked the protein expression of IL-5 in BAL fluid. The concentration of ovalbumin-specific IgE in BAL fluid was weakly inhibited by the LI extract.


CONCLUSIONS
These results suggest that the LI extract may be used as a valuable agent for treating allergic diseases such as asthma due to its anti-inflammatory property.
Yang
Eun Ju
EJ
Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Yeuongdu-dong, Jung-gu, Daejeon, Republic of Korea.
Lee
Ji-Sook
JS
Song
Bo Bae
BB
Yun
Chi-Young
CY
Kim
Dong-Hee
DH
Kim
In Sik
IS
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism*; D004802:Eosinophilia / Q000188:drug therapy; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D020397:Goblet Cells / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D031563:Lagerstroemia; D007964:Leukocytosis / Q000188:drug therapy; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009093:Mucus / Q000378:metabolism; D010047:Ovalbumin; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D039981:Pyroglyphidae; D017382:Reactive Oxygen Species / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D010936:Plant Extracts; D017382:Reactive Oxygen Species; D007073:Immunoglobulin E; D010047:Ovalbumin